Journal of Molecular Oncology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Molecular Oncology Research (2025) Volume 9, Issue 2

Decoding cancer through epigenetic modifications: New frontiers in molecular oncology research

Mikael J Pittet *

Department of Oncology, University of Geneva, Switzerland

*Corresponding Author:
Mikael J Pittet
Department of Oncology, University of Geneva, Switzerland
E-mail: mikael.pittet@unige.ch

Received: 01-May-2025, Manuscript No. AAMOR -25-166705; Editor assigned: 02-May-2025, PreQC No. AAMOR -25-166705(PQ); Reviewed: 18-May-2025, QC No. AAMOR -25-166705; Revised: 22-May-2025, Manuscript No. AAMOR -25-166705(R); Published: 29-May-2025, DOI: 10.35841/ aamor-9.2.286

Citation: : Pittet J M. Decoding cancer through epigenetic modifications: New frontiers in molecular oncology research. J Mol Oncol Res. 2025;9(2):286.

Visit for more related articles at Journal of Molecular Oncology Research

Introduction

Cancer is a multifaceted disease driven not only by genetic mutations but also by complex epigenetic alterations that regulate gene expression without changing the DNA sequence. The study of epigenetic modifications including DNA methylation, histone modifications, and non-coding RNA activity has emerged as a critical component of molecular oncology research. Understanding these reversible changes offers promising avenues for novel diagnostics and targeted therapies, marking a new chapter in personalized cancer treatment [1].

Unlike genetic mutations that permanently alter the genome, epigenetic modifications dynamically regulate gene activity and cellular identity. Aberrant epigenetic changes can silence tumor suppressor genes or activate oncogenes, contributing to cancer initiation, progression, and metastasis. Recent technological advances have enabled comprehensive mapping of the cancer epigenome, revealing specific patterns associated with distinct cancer types and stages [2].

Role of DNA Methylation and Histone Modifications in Cancer. DNA methylation, the addition of methyl groups to cytosine bases predominantly in CpG islands, is one of the most studied epigenetic mechanisms. In many cancers, hypermethylation of promoter regions leads to the silencing of critical tumor suppressor genes, while global hypomethylation can cause genomic instability and activation of oncogenic pathways. Histone proteins around which DNA is wrapped also undergo chemical modifications such as acetylation, methylation, and phosphorylation. These modifications alter chromatin structure and accessibility, thereby regulating gene expression. Dysregulation of histone-modifying enzymes, like histone deacetylases (HDACs) and histone methyltransferases (HMTs), has been implicated in various malignancies, offering targets for therapeutic intervention [3].

Epigenetic Biomarkers in Molecular Oncology. The reversible nature of epigenetic marks positions them as attractive biomarkers for early cancer detection and prognosis. DNA methylation profiles from liquid biopsies, including circulating tumor DNA, provide minimally invasive tools for monitoring disease progression and treatment response. Integration of epigenetic data with genomic and transcriptomic information through molecular oncology research enhances our ability to stratify patients and predict outcomes. This multi-omic approach fosters precision oncology, tailoring interventions to the molecular characteristics of each tumor.

Epigenetic Therapies: Current Landscape and Future Prospects. Therapeutic agents targeting epigenetic regulators have gained momentum, particularly HDAC inhibitors and DNA methyltransferase inhibitors, which have been approved for certain hematological cancers. These drugs can reverse aberrant epigenetic silencing and re-activate tumor suppressor pathways.

Emerging epigenetic therapies focus on novel targets such as bromodomain and extraterminal (BET) proteins and histone methyltransferases, expanding the armamentarium against resistant and aggressive cancers. Combination strategies integrating epigenetic drugs with immunotherapy or chemotherapy are under investigation to enhance efficacy and overcome resistance mechanisms. Challenges and Emerging Technologies. Despite encouraging progress, challenges remain in fully harnessing epigenetic modifications for cancer treatment. Tumor heterogeneity and the complexity of epigenetic networks necessitate precise targeting to avoid off-target effects [4].

Advanced technologies like single-cell epigenomics and CRISPR-based epigenetic editing are revolutionizing our understanding and manipulation of the cancer epigenome. These tools allow the dissection of epigenetic regulation at unparalleled resolution and the potential correction of aberrant marks with high specificity. Ethical and Clinical Considerations. As epigenetic therapies advance, ethical questions regarding long-term effects and heritable epigenetic changes must be addressed. Clinical trials demand rigorous design to evaluate safety and efficacy, especially in combination regimens. Accessibility and affordability of cutting-edge molecular diagnostics and therapies also pose challenges that require coordinated efforts among researchers, clinicians, regulators, and policymakers [5].

Conclusion       

Epigenetic modifications constitute a fundamental layer of cancer biology with profound implications for molecular oncology research and clinical practice. Decoding and therapeutically targeting the cancer epigenome open exciting opportunities for earlier diagnosis, personalized treatment, and improved patient outcomes. Ongoing innovations and multidisciplinary collaboration will be key to translating epigenetic insights into transformative cancer care.

References

  1. Agha RA, Franchi T, Sohrabi C, et al. The SCARE 2020 guideline: Updating consensus surgical case report (SCARE) guidelines. Int J Surg. 2020;84:226-30.

    2. Indexed at, Google Scholar, Cross Ref

  2. Marone J, Patel S, Page M, et al. Signet cell carcinoma of the colon in a 17 year old child. J Surg Case Rep. 2012; 12(9):3.

    3. Indexed at, Google Scholar, Cross Ref

  3. Jasperson KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. Gastroenterol. 2010; 138(6):2044-58.

    4.  Google Scholar, Cross Ref

  4. De Rosa M, Pace U, Rega D, et al. Genetics diagnosis and management of colorectal cancer. Oncol Rep. 2015; 34(3):1087-096.

    5. Indexed at, Google Scholar, Cross Ref

  5. Isidori AM, Pozza C, Esposito K, et al. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010; 7:1139-146.

    6. Indexed at, Google Scholar, Cross Ref

  6. Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers version 2. 2020 NCCN clinical practice guidelines in oncology.J Natl Compr Cancer Netw. 2020; 18:873-98.

    7. Indexed at, Google Schoalr, Cross Ref

  7. Seiwert TY, Foster CC, Blair EA, et al. OPTIMA: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019; 30:297-02.

    8. Indexed at, Google Scholar, Cross Ref

  8. Chen AM, Felix C, Wang P, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm phase 2 study. Lancet Oncol. 2017; 18:803-11.

    9. Indexed at, Google Scholar, Cross Ref

  9. Lassen P, Lacas B, Pignon J, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project. Radiother Oncol. 126 2018; 126:107-15.

    10. Indexed at, Google Scholar, Cross Ref

  10. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1- weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging. 1999; 10: 223-32.

    11. Indexed at, Google Scholar, Cross Ref

     

Get the App